ALLMedicine™ Hypereosinophilic Syndrome Center

Feb 24th, 2021 - Mepolizumab (Nucala) has been approved to treat hypereosinophilic syndrome.Nurses should read the package insert for directions on how to reconstitute and administer the drug subcutaneously. Patient education will be needed regarding use of the au...

Feb 5th, 2021 - A previously healthy 40-year-old man was referred to our emergency department with pruritic skin lesions and dyspnoea. Laboratory investigation revealed hypereosinophilia. Further diagnostic work-up confirmed the diagnosis of idiopathic hypereosin...

Jan 29th, 2021 - A high functioning 74-year-old man with systemic lupus erythematosus presented to the emergency department with acute anxiety. He was found to have elevated cardiac enzymes and admitted to the cardiology service for investigation. In hospital, he ...

Jan 25th, 2021 - Hypereosinophilic syndrome is defined as persistent eosinophilia in the blood for more than 6 months, without any identifiable cause and with end-organ involvement evidence. Cardiac manifestations of HES include heart failure due to restrictive ca...

Jan 25th, 2021 - To report the case of a patient presenting with newly diagnosed atypical hemolytic uremic syndrome (aHUS) and Purtscher-like retinopathy. Observational case report and review of literature. A 38-year-old female presented with 3 months of rashes, f...

Feb 24th, 2021 - Mepolizumab (Nucala) has been approved to treat hypereosinophilic syndrome.Nurses should read the package insert for directions on how to reconstitute and administer the drug subcutaneously. Patient education will be needed regarding use of the au...

Feb 5th, 2021 - A previously healthy 40-year-old man was referred to our emergency department with pruritic skin lesions and dyspnoea. Laboratory investigation revealed hypereosinophilia. Further diagnostic work-up confirmed the diagnosis of idiopathic hypereosin...

Jan 29th, 2021 - A high functioning 74-year-old man with systemic lupus erythematosus presented to the emergency department with acute anxiety. He was found to have elevated cardiac enzymes and admitted to the cardiology service for investigation. In hospital, he ...

Jan 25th, 2021 - Hypereosinophilic syndrome is defined as persistent eosinophilia in the blood for more than 6 months, without any identifiable cause and with end-organ involvement evidence. Cardiac manifestations of HES include heart failure due to restrictive ca...

Jan 25th, 2021 - To report the case of a patient presenting with newly diagnosed atypical hemolytic uremic syndrome (aHUS) and Purtscher-like retinopathy. Observational case report and review of literature. A 38-year-old female presented with 3 months of rashes, f...

Sep 27th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

Sep 27th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.

Mar 6th, 2017 - Comment In addition to CML, imatinib has been approved for acute lymphoblastic leukemia, myelodysplastic syndromes, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and G.

Apr 2nd, 2006 - Action Points Be aware that this study found Gleevec effective and safe in patients with idiopathic hypereosinophilic syndrome (HES) who have a translocation between the FIP1L1 and PDGFR genes. This is an off-label use of Gleevec. This study was p...